<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://ipharmag.com/article/foundayo-vs-wegovy-pill-glp1-weight-loss-pills-compared</loc>
    <news:news>
      <news:publication>
        <news:name>iPharmag</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-25T11:15:25+00:00</news:publication_date>
      <news:title>Foundayo vs. the Wegovy Pill: How the Two GLP-1 Weight-Loss Pills Compare</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://ipharmag.com/article/roche-sefaxersen-iga-nephropathy-phase3-kidney</loc>
    <news:news>
      <news:publication>
        <news:name>iPharmag</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-25T10:59:37+00:00</news:publication_date>
      <news:title>Roche’s Kidney Drug Posts Positive Phase 3 Data in a Crowding IgA Nephropathy Race</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://ipharmag.com/article/iga-nephropathy-explained-symptoms-causes-treatment</loc>
    <news:news>
      <news:publication>
        <news:name>iPharmag</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-25T10:59:37+00:00</news:publication_date>
      <news:title>IgA Nephropathy Explained: Symptoms, Causes, Diagnosis and the New Treatments</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://ipharmag.com/article/fda-panel-endorses-grail-galleri-multi-cancer-test</loc>
    <news:news>
      <news:publication>
        <news:name>iPharmag</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-25T10:59:37+00:00</news:publication_date>
      <news:title>FDA Advisers Endorse the First Blood Test That Screens for Many Cancers</news:title>
    </news:news>
  </url>
</urlset>
